Eisai CoESALF 69 Debt-to-EBITDA is 12.97 as of Mar. 2026, which is 770% above its 10-year median of 1.49. GuruFocus rates ESALF with a GF Score™ of 69/100 and a GF Value™ of $35.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Eisai Co ranks worse than 54.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Eisai Co's Debt-to-EBITDA or its related term are showing as below:
ESALF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.55 Med: 1.49 Max: 2.44
Current: 1.94
During the past 13 years, the highest Debt-to-EBITDA Ratio of Eisai Co was 2.44. The lowest was 0.55. And the median was 1.49.
ESALF's Debt-to-EBITDA is ranked worse than 54.93% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs ESALF: 1.94
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Eisai Co Debt-to-EBITDA Related Terms
Eisai Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Eisai Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eisai Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Eisai Co (ESALF) has a Debt-to-EBITDA of 12.97 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eisai Co. This is 770% above median its historical median of 1.49. Over the past decade, Eisai Co's Debt-to-EBITDA has ranged from 0.55 to 2.44. According to the industry distribution chart, Eisai Co ranks #379 out of 690 companies in the Drug Manufacturers industry, placing it in the top 54.9%.
Is Eisai Co's Debt-to-EBITDA too high?
Eisai Co's current Debt-to-EBITDA of 12.97 is 770% above median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 2.44. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Eisai Co's value of 12.97 is 676.6% above this industry median. Based on the distribution chart, Eisai Co ranks #379 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #379 out of 690 companies for Debt-to-EBITDA. This places Eisai Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Eisai Co's value of 12.97 is 676.6% above this benchmark. Historically, Eisai Co's own Debt-to-EBITDA has ranged from 0.55 to 2.44 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.67, Eisai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current Debt-to-EBITDA of 12.97 is 676.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eisai Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Debt-to-EBITDA is 12.97, which is 770% above median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.04, compared to a current price of $25.00 — trading 28.7% below its estimated fair value. The current Debt-to-EBITDA is 12.97, which is 770% above median its 10-year median of 1.49 and 676.6% above the Drug Manufacturers industry median of 1.67. Eisai Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Eisai Co (ESALF), the current Debt-to-EBITDA is 12.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 28.7% below its estimated GF Value™ of $35.04.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
Debt-to-EBITDA: 12.97 (770% above median its 10-year median of 1.49)
GF Value™: $35.04 vs. price of $25.00 (28.7% below fair value)
Industry Position: 676.6% above the Drug Manufacturers median (#379 of 690)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for ESALF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
